NASDAQ: KALAKala Bio Inc Stock
$0.69-0.12 (-14.81%)
Updated Aug 28, 2026
KALA Price
$0.69
Fair Value Price
$0.93
Market Cap
$13.34M
52 Week Low
$0.59
52 Week High
$1,030.00
P/E
-0.02x
P/B
1.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$20M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KALA Overview
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KALA's potential to beat the market
- KALA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
KALA
RankedUnranked of 58
RankedUnranked of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $59.78 | A | |
| $34.87 | A | |
| $6.32 | A |
Be the first to know about important KALA news, forecast changes, insider trades & much more!
KALA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KALA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KALA ($0.69) is undervalued by 25.6% relative to our estimate of its Fair Value price of $0.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KALA ($0.69) is significantly undervalued by 25.6% relative to our estimate of its Fair Value price of $0.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KALA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KALA due diligence checks available for Premium users.
Valuation
KALA fair value
Fair Value of KALA stock based on Discounted Cash Flow (DCF)
Price
$0.69
Fair Value
$0.93
Undervalued by
25.60%
KALA ($0.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KALA ($0.69) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KALA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KALA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
2.6x
Market
40.56x
KALA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.48x
Industry
1.65x
KALA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KALA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
KALA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$1.5M
Debt to equity
0.17
KALA's short-term assets ($10.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KALA's short-term assets ($10.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KALA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KALA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$0.0
Financing
$0.0
KALA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KALA vs Pharmaceutical Stocks
Kala Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.